The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Self-citationYoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Self-citationFriend, C., Scher, W., Holland, J. G., & Sato, T. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.2.378 · Cited by 1,352
Epigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Self-citationA class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citationKelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Self-citationErythroleukemic Differentiation
Marks, P. A., & Rifkind, R. A. (1978) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.47.070178.002223 · Cited by 680
Self-citationKelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Self-citationButler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Self-citationApoptotic and autophagic cell death induced by histone deacetylase inhibitors
Shao, Y., Gao, Z., Marks, P. A., & Jiang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408345102 · Cited by 605
Self-citationGui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Self-citationPeart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 539
Self-citationMitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536759100 · Cited by 531
Self-citationHistone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
Self-citationUngerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
Self-citationCLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
Rapid Alteration of MicroRNA Levels by Histone Deacetylase Inhibition
Scott, G. K., Mattie, M. D., Berger, C. E., Benz, S. C., & Benz, C. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3632 · Cited by 492
Histone deacetylase inhibitors in cancer therapy
Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 449
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., & Marks, P. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5705 · Cited by 420
Self-citationO'Connor, O. A., Heaney, M. L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9679 · Cited by 404
Self-citationA new group of potent inducers of differentiation in murine erythroleukemia cells.
Reuben, R. C., Wife, R. L., Breslow, R., Rifkind, R. A., & Marks, P. A. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.3.862 · Cited by 370
Self-citationHistone deacetylase inhibitors
Monneret, C. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.10.001 · Cited by 338
Kelly, W. K., & Marks, P. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0106 · Cited by 330
Self-citationHistone deacetylase inhibitors: discovery and development as anticancer agents
Marks, P. A., & Dokmanovic, M. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.12.1497 · Cited by 318
Self-citationEpigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Fuino, L., Bali, P., Wittmann, S., Donapaty, S., Guo, F., Yamaguchi, H., Wang, H., Atadja, P. W., & Bhalla, K. N. (2003) · PubMed · Cited by 263
Zhang, C., Richon, V., Ni, X., Talpur, R., & Duvic, M. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23925.x · Cited by 242
Rosato, R. R., Almenara, J. A., Dai, Y., & Grant, S. (2003) · PubMed · Cited by 232
Tanaka, M., Levy, J., Terada, M., Breslow, R., Rifkind, R. A., & Marks, P. A. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.3.1003 · Cited by 220
Self-citationHistone acetyltransferases and deacetylases in the control of cell proliferation and differentiation
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)86002-x · Cited by 205
Guo, F., Sigua, C., Tao, J., Bali, P., George, P., Li, Y., Wittmann, S., Moscinski, L., Atadja, P., & Bhalla, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2629 · Cited by 202
Bali, P., Pranpat, M., Swaby, R., Fiskus, W., Yamaguchi, H., Balasis, M., Rocha, K., Wang, H.-G., Richon, V., & Bhalla, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0344 · Cited by 184
Induction of transformed cells to terminal differentiation and the modulation of gene expression.
Marks, P. A., Sheffery, M., & Rifkind, R. A. (1987) · PubMed · Cited by 160
Self-citationHistone Deacetylase Inhibitors in Programmed Cell Death and Cancer Therapy
Marks, P. A., & Jiang, X. (2005) · Cell Cycle · doi:10.4161/cc.4.4.1564 · Cited by 142
Self-citationAndreeff, M., Stone, R. M., Michaeli, J., Cw, Y., Tong, W., Sogoloff, H., Ervin, T. J., Kufe, D. W., Rifkind, R. A., & Marks, P. (1992) · Blood · doi:10.1182/blood.v80.10.2604.2604 · Cited by 124
Self-citationHistone deacetylase inhibitors and cancer: from cell biology to the clinic
Hess‐Stumpp, H. (2005) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2004.12.010 · Cited by 123
Inhibitors of histone deacetylase are potentially effective anticancer agents.
Marks, P. A., Rifkind, R. A., Richon, V. M., & Breslow, R. (2001) · PubMed · Cited by 119
Self-citationHistone Deacetylase: A Target for Antiproliferative and Antiprotozoal Agents
Meinke, P. T., & Liberator, P. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373787 · Cited by 103
Histone Deacetylase Inhibitors: Latest Developments, Trends and Prospects
Moradei, O. M., Maroun, C. R., Paquin, I., & Vaisburg, A. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011054866946 · Cited by 84
Potent cytodifferentiating agents related to hexamethylenebisacetamide.
Breslow, R., Jursic, B., Yan, Z. F., Friedman, E., Leng, L., Ngo, L., Rifkind, R. A., & Marks, P. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5542 · Cited by 63
Self-citationYoshida, C., & Melo, J. V. (2004) · International Journal of Hematology · doi:10.1532/ijh97.04032 · Cited by 47
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S. R. S., Wang, J. G., Frankel, S., Lis, J., & Duvic, M. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7500 · Cited by 42
[Histone-deacetylases inhibitors: from TSA to SAHA].
Peixoto, P., & Lansiaux, A. (2006) · PubMed · Cited by 17
Cited by
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Self-citation
Metadata
- Authors
- Marks, P. A., & Breslow, R.
- Venue
- Nature Biotechnology
- Published
- 2007-01
- Volume
- 25
- Issue
- 1
- Pages
- 84-90
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2087966689
- Cited by
- 1,196
- References
- 48
- FWCI
- 29.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.